Monitor for any subsequent 424B prospectus supplement indicating Armistice Capital's actual resale activity, which would signal near-term selling pressure. Also watch for any cash exercise of the warrants, which would provide a modest capital infusion but further dilute existing shareholders.
Executive Summary
BioLineRx filed an F-1 registration statement to register 2,023,382 ADSs for resale by Armistice Capital, the sole selling shareholder, which were issued as warrants in the August 2026 private placement. The company will not receive any proceeds from the resale, but may receive up to $5.6 million if the warrants are exercised for cash. The filing is a routine procedural step required by the August 2026 offering terms and does not reflect any new financing or change in business operations.
Key Facts
- Registration of 2,023,382 ADSs (representing 1,214,029,200 ordinary shares) for resale by Armistice Capital, issued as warrants in the August 2026 private placement.
- BioLineRx will not receive any proceeds from the resale; all net proceeds go to the selling shareholder.
- If all warrants are exercised for cash, BioLineRx would receive $5.6 million for R&D, working capital, and general corporate purposes.
- Armistice Capital holds 2,114,793,000 ordinary shares (including warrants) prior to the offering, representing a 21.4% stake post-offering assuming full exercise and sale.
- The company's auditor included a going concern explanatory paragraph in the FY2025 financial statements.
- ADSs trade on Nasdaq under BLRX at $2.56 as of September 23, 2026; ordinary shares trade on TASE at NIS 0.013 ($0.0043).
Financial Impact
Up to $5.6 million in potential cash proceeds if all warrants are exercised for cash; no proceeds from the resale itself.
Risk Factors
- Potential near-term selling pressure from Armistice Capital's resale of up to 2,023,382 ADSs.
- Further dilution if warrants are exercised for cash, adding up to 1.2 billion ordinary shares.
- Going concern uncertainty noted in the FY2025 audit report, indicating ongoing capital needs.
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| F-1 Filing (Primary) | 0001178913-26-004612 |
| Exhibit: ex107.htm | 0001178913-26-004612 |
| Exhibit: exhibit_5-1.htm | 0001178913-26-004612 |
| Exhibit: exhibit_23-1.htm | 0001178913-26-004612 |
| Document: 0001178913-26-004612-index-headers.html | 0001178913-26-004612 |
| Document: 0001178913-26-004612-index.html | 0001178913-26-004612 |
| Document: 0001178913-26-004612.txt | 0001178913-26-004612 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 6-K | $2.04 | awaiting T+20 | — | $2.01 (−1.47%) |
Oct 5, 2026 22d ago | EFFECT | $2.32 | awaiting T+20 | — | $2.01 (+13.36%) |
Sep 25, 2026 4w ago | F-1 | $2.43 $2.00 | ▼ −17.70% | ▼ −17.66% | $2.01 (−17.28%) |
Sep 10, 2026 6w ago | 6-K | $2.57 $2.21 | ▼ −13.99% | ▼ −16.12% | $2.01 (−21.77%) |
Aug 31, 2026 8w ago | 424B5 | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.01 (+28.21%) |
Aug 31, 2026 8w ago | 6-K | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.01 (+28.21%) |
Aug 31, 2026 8w ago | 6-K | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.01 (+28.21%) |
Aug 28, 2026 8w ago | 6-K | $2.60 $2.43 | ▲ +6.54% | ▲ +6.80% | $2.01 (+22.69%) |
Aug 28, 2026 8w ago | Press Release | $2.60 $2.43 | ▲ +6.54% | ▲ +6.80% | $2.01 (+22.69%) |
Jul 8, 2026 15w ago | 6-K | $3.01 $2.72 | ▼ −9.73% | ▼ −13.01% | $2.01 (−33.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers